Supernus Pharmaceuticals reported $35.14M in Pre-Tax Profit for its fourth fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Pre Tax Profit Change
Abbott ABT:US USD 2.17B 316M
Canopy Growth Corp WEED:CN CAD -267104000 43.41M
Cara Therapeutics CARA:US USD -30339000 7.16M
Corcept Therapeutics CORT:US USD 24.28M 8.73M
Eisai 4523:JP JPY 9.46B 11.04B
Eli Lilly And LLY:US USD 2.04B 38.3M
Horizon Pharma HZNP:US USD 340.7M 25.6M
JAZZ PHA JAZZ:US USD -46767000 464.14M
Marinus Pharmaceuticals MRNS:US USD -32675000 342K
Pacira Pharmaceuticals PCRX:US USD 46.48M 4.25M
Perrigo Ordinary Shares PRGO:US USD 112.7M 16M
Pfizer PFE:US USD 7.38B 3.3B
Revance Therapeutics RVNC:US USD -145952000 61.96M
Supernus Pharmaceuticals SUPN:US USD 35.14M 35.58M
United Therapeutics UTHR:US USD 178.8M 133.7M
Xeris Pharmaceuticals Inc XERS:US USD -13268000 8.9M